

Caterina Stelitano

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3123242/caterina-stelitano-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

95
papers

5,271
citations

37
h-index

72
g-index

96
ext. papers

6,006
ext. citations

4.8
avg, IF

4.29
L-index

#	Paper	IF	Citations
95	Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study. <i>Journal of Clinical Oncology</i> , 2021 , JCO2101234	2.2	7
94	Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib. <i>Cancers</i> , 2021 , 13,	6.6	5
93	Long-term results of the MCL01 phase II trial of rituximab plus HyperCVAD alternating with high-dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma. <i>British Journal of Haematology</i> , 2021 , 192, 1011-1014	4.5	2
92	A brief rituximab, bendamustine, mitoxantrone (R-BM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL). <i>British Journal of Haematology</i> , 2021 , 193, 280-289	4.5	3
91	Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2021 , 8, e34-e44	14.6	9
90	ALK-negative anaplastic large cell lymphoma: features and outcomes of 235 patients from the International T-Cell Project. <i>Blood Advances</i> , 2021 , 5, 640-648	7.8	6
89	The conditional survival analysis of relapsed DLBCL after autologous transplant: a subgroup analysis of LY.12 and CORAL. <i>Blood Advances</i> , 2020 , 4, 2011-2017	7.8	4
88	Long-lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for or failed autologous transplantation. <i>Hematological Oncology</i> , 2020 , 38, 257-265	1.3	4
87	Relapsing/refractory HL after autotransplantation: which treatment?. <i>Acta Biomedica</i> , 2020 , 91, 30-40	3.2	
86	Clinical characteristics of interim-PET negative patients with a positive end PET from the prospective HD08-01 FIL study. <i>Annals of Hematology</i> , 2020 , 99, 283-291	3	4
85	Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trial. <i>Haematologica</i> , 2019 , 104, 2241-2248	6.6	6
84	MYC protein expression scoring and its impact on the prognosis of aggressive B-cell lymphoma patients. <i>Haematologica</i> , 2019 , 104, e25-e28	6.6	17
83	Bleomycin, vinblastine and dacarbazine combined with nonpegylated liposomal doxorubicin (MBVD) in elderly (≥70 years) or cardiopathic patients with Hodgkin lymphoma: a phase-II study from Fondazione Italiana Linfomi (FIL). <i>Leukemia and Lymphoma</i> , 2019 , 60, 2890-2898	1.9	5
82	A rare case of appendicular skeleton localization in a patient with chronic lymphocytic leukemia successfully treated with salvage radiation therapy. <i>Advances in Radiation Oncology</i> , 2018 , 3, 121-124	3.3	
81	Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma. <i>Journal of Clinical Oncology</i> , 2018 , 36, 689-696	2.2	81
80	Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study. <i>British Journal of Haematology</i> , 2018 , 183, 755-765	4.5	25
79	Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi. <i>Haematologica</i> , 2017 , 102, e203-e206	6.6	17

78	Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial. <i>Lancet Haematology, the</i> , 2017 , 4, e137-e146	14.6	22
77	Prognostic models for primary mediastinal (thymic) B-cell lymphoma derived from 18-FDG PET/CT quantitative parameters in the International Extranodal Lymphoma Study Group (IELSG) 26 study. <i>British Journal of Haematology</i> , 2017 , 178, 588-591	4.5	15
76	Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1905-1912	2.2	98
75	Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study. <i>Lancet Oncology, The</i> , 2017 , 18, 1076-1088	21.7	72
74	A Multicenter Phase II Study of Twice-Weekly Bortezomib plus Rituximab in Patients with Relapsed Follicular Lymphoma: Long-Term Follow-Up. <i>Acta Haematologica</i> , 2017 , 137, 7-14	2.7	4
73	Positron Emission Tomography/Computed Tomography Assessment After Immunochemotherapy and Irradiation Using the Lugano Classification Criteria in the IELSG-26 Study of Primary Mediastinal B-Cell Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017 , 97, 42-49	4	21
72	Reduced intensity VEPEMB regimen compared with standard ABVD in elderly Hodgkin lymphoma patients: results from a randomized trial on behalf of the Fondazione Italiana Linfomi (FIL). <i>British Journal of Haematology</i> , 2016 , 172, 879-88	4.5	25
71	Lenalidomide versus investigator choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial. <i>Lancet Oncology, The</i> , 2016 , 17, 319-331	21.7	103
70	Interim Positron Emission Tomography Response-Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1376-85	2.2	101
69	B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: a randomized, phase II trial of the Fondazione Italiana Linfomi (FIL). <i>Leukemia and Lymphoma</i> , 2016 , 57, 2375-81	1.9	5
68	A phase II study of bendamustine in combination with rituximab as initial treatment for patients with indolent non-follicular non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2016 , 57, 880-7	1.9	8
67	Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1175-81	2.2	74
66	The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin lymphoma: a retrospective, European, multicentre cohort study. <i>Lancet Haematology, the</i> , 2016 , 3, e467-e479	14.6	44
65	The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study. <i>Haematologica</i> , 2015 , 100, 517-24	6.6	4
64	Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma: a Fondazione Italiana Linfomi phase II study. <i>Leukemia and Lymphoma</i> , 2015 , 56, 3281-7	1.9	19
63	Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: a prospective multicenter evaluation in 173 patients by the Lymphoma Italian Foundation (FIL). <i>Leukemia and Lymphoma</i> , 2015 , 56, 921-6	1.9	90
62	The prognostic value of positron emission tomography performed after two courses (INTERIM-PET) of standard therapy on treatment outcome in early stage Hodgkin lymphoma: A multicentric study by the fondazione italiana linfomi (FIL). <i>American Journal of Hematology</i> , 2015 , 90, 499-503	7.1	38
61	Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma. <i>Blood</i> , 2015 , 126, 950-6	2.2	111

60	A Patient with Chronic Lymphocytic Leukemia and Bone Localization: A Case Report. <i>Blood</i> , 2015 , 126, 5301-5301	2.2	1
59	[18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 Study. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1769-75	2.2	120
58	Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi. <i>Haematologica</i> , 2014 , 99, 489-96	6.6	46
57	Outcome of frail elderly patients with diffuse large B-cell lymphoma prospectively identified by Comprehensive Geriatric Assessment: results from a study of the Fondazione Italiana Linfomi. <i>Leukemia and Lymphoma</i> , 2014 , 55, 38-43	1.9	54
56	MATILDE chemotherapy regimen for primary CNS lymphoma: results at a median follow-up of 12 years. <i>Neurology</i> , 2014 , 82, 1370-3	6.5	33
55	Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy. <i>Hematological Oncology</i> , 2013 , 31, 143-50	1.3	53
54	Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2013 , 160, 207-15	4.5	51
53	R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1506-13	2.2	193
52	Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi/Grupo de Estudos em Moléstias Onco-Hematológicas retrospective study. <i>Leukemia and Lymphoma</i> , 2013 , 54, 53-7	1.9	36
51	Anemia prevalence and treatment practice in patients with non-myeloid tumors receiving chemotherapy. <i>Cancer Management and Research</i> , 2013 , 5, 205-14	3.6	3
50	Chlamydophila psittaci eradication with doxycycline as first-line targeted therapy for ocular adnexae lymphoma: final results of an international phase II trial. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2988-94	2.2	125
49	Role of glutathione-S-transferase (GST) polymorphisms in patients with advanced Hodgkin lymphoma: results from the HD2000 GISL trial. <i>Leukemia and Lymphoma</i> , 2012 , 53, 406-10	1.9	3
48	Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly "fit" patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi. <i>Leukemia and Lymphoma</i> , 2012 , 53, 581-8	1.9	56
47	Fludarabine, cyclophosphamide, and rituximab in patients with advanced, untreated, indolent B-cell nonfollicular lymphomas: phase 2 study of the Italian Lymphoma Foundation. <i>Cancer</i> , 2012 , 118, 3954-61	6.4	18
46	Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi. <i>British Journal of Haematology</i> , 2012 , 156, 346-53	4.5	101
45	Tumor burden in Hodgkin lymphoma can be reliably estimated from a few staging parameters. <i>Oncology Reports</i> , 2012 , 28, 815-20	3.5	7
44	Chemoresistance as a function of the pretherapy tumor burden and the chemotherapy regimen administered: differences observed with 2 current chemotherapy regimens for advanced Hodgkin lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011 , 11, 396-402	2	10
43	Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses. <i>British Journal of Haematology</i> , 2011 , 152, 551-60	4.5	115

42	Single-dose palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with aggressive non-Hodgkin lymphoma receiving moderately emetogenic chemotherapy containing steroids: results of a phase II study from the Gruppo Italiano per lo Studio dei Linfomi (GISL). <i>Supportive Care in Cancer</i> , 2011 , 19, 1505-10	3.9	18
41	Phase II fludarabine and cyclophosphamide for the treatment of indolent B cell non-follicular lymphomas: final results of the LL02 trial of the Gruppo Italiano per lo Studio dei Linfomi (GISL). <i>Annals of Hematology</i> , 2011 , 90, 323-30	3	10
40	Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin lymphoma: a study from the Intergruppo Italiano Linfomi. <i>Journal of Clinical Oncology</i> , 2011 , 29, 4227-33	2.2	38
39	Clinical relevance of the dose of cytarabine in the upfront treatment of primary CNS lymphomas with methotrexate-cytarabine combination. <i>Oncologist</i> , 2011 , 16, 336-41	5.7	27
38	Long term outcome of patients with localized aggressive non-Hodgkin lymphoma treated with PROMECE-CYTABOM plus involved-field radiation therapy: a study by the Gruppo Italiano Studio Linfomi. <i>Leukemia and Lymphoma</i> , 2010 , 51, 422-9	1.9	2
37	ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. <i>Journal of Clinical Oncology</i> , 2009 , 27, 805-11	2.2	206
36	Bisphosphonates-associated osteonecrosis of the jaw: A long-term follow-up of a series of 35 cases observed by GISL and evaluation of its frequency over time. <i>American Journal of Hematology</i> , 2009 , 84, 850-2	7.1	7
35	Anthracycline-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma. <i>Cancer</i> , 2009 , 115, 1906-13	6.4	5
34	Response-guided ABVD chemotherapy plus involved-field radiation therapy for intermediate-stage Hodgkin lymphoma in the pre-positron emission tomography era: a Gruppo Italiano Studio Linfomi (GISL) prospective trial. <i>Clinical Lymphoma and Myeloma</i> , 2009 , 9, 138-44		8
33	The early- and intermediate-term toxicity to primitive hematopoietic progenitor cells of three chemotherapy regimens for advanced Hodgkin lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2009 , 9, 425-9		3
32	High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. <i>Lancet, The</i> , 2009 , 374, 1512-20	4.0	478
31	Bone marrow stem cell damage after three different chemotherapy regimens for advanced Hodgkin lymphoma. <i>Oncology Reports</i> , 2009 , 21, 1029-35	3.5	5
30	Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior. <i>Blood</i> , 2009 , 114, 4696-702	2.2	95
29	Secondary malignancies after treatment for indolent non-Hodgkin lymphoma: a 16-year follow-up study. <i>Haematologica</i> , 2008 , 93, 398-404	6.6	73
28	Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients. <i>Leukemia and Lymphoma</i> , 2007 , 48, 56-64	1.9	74
27	Low tolerance and high toxicity of thalidomide as maintenance therapy after double autologous stem cell transplant in multiple myeloma patients. <i>European Journal of Haematology</i> , 2007 , 78, 35-40	3.8	12
26	Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin lymphoma: a report from a joint Italian-Danish study. <i>Journal of Clinical Oncology</i> , 2007 , 25, 3746-52	2.2	667
25	Prognostic relevance of serum beta2 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens. A GISL study. <i>Haematologica</i> , 2007 , 92, 1482-8	6.6	30

24	Assessment of the frequency of additional cancers in patients with splenic marginal zone lymphoma. <i>European Journal of Haematology</i> , 2006 , 76, 134-40	3.8	12
23	The length of treatment of aggressive non-Hodgkin lymphomas established according to the international prognostic index score: long-term results of the GISL LA03 study. <i>European Journal of Haematology</i> , 2006 , 76, 217-29	3.8	7
22	High-dose therapy and autologous peripheral blood stem cells transplantation followed by a very low reduced intensity regimen with fludarabine + cyclophosphamide and allograft improve complete remission rate in de novo multiple myeloma patients. <i>American Journal of Hematology</i> , 2006 , 81, 973-8	7.1	5
21	Incidence of second neoplasia in patients with B-cell chronic lymphocytic leukemia treated with chlorambucil maintenance chemotherapy. <i>Leukemia and Lymphoma</i> , 2006 , 47, 2314-20	1.9	27
20	IgV gene intracлонаl diversification and clonal evolution in B-cell chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2006 , 133, 50-8	4.5	16
19	The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin disease. <i>Haematologica</i> , 2006 , 91, 475-81	6.6	190
18	Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation. <i>Leukemia Research</i> , 2005 , 29, 961-6	2.7	51
17	Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma. <i>Oncogene</i> , 2005 , 24, 2461-73	9.2	107
16	Characterization of oncogene dysregulation in multiple myeloma by combined FISH and DNA microarray analyses. <i>Genes Chromosomes and Cancer</i> , 2005 , 42, 117-27	5	44
15	Administration of recombinant human erythropoietin alpha before autologous stem cell transplantation reduces transfusion requirement in multiple myeloma patients. <i>Supportive Care in Cancer</i> , 2005 , 13, 182-7	3.9	6
14	ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. <i>Journal of Clinical Oncology</i> , 2005 , 23, 9198-207	2.2	144
13	Clinical relevance of immunophenotype in a retrospective comparative study of 297 peripheral T-cell lymphomas, unspecified, and 496 diffuse large B-cell lymphomas: experience of the Intergruppo Italiano Linfomi. <i>Cancer</i> , 2004 , 101, 1601-8	6.4	39
12	CD1d is expressed on B-chronic lymphocytic leukemia cells and mediates alpha-galactosylceramide presentation to natural killer T lymphocytes. <i>International Journal of Cancer</i> , 2004 , 109, 402-11	7.5	69
11	Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial. <i>European Journal of Cancer</i> , 2004 , 40, 1682-8	7.5	99
10	Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. <i>Blood</i> , 2004 , 103, 2474-9	2.2	460
9	Treatment of indolent B-Cell nonfollicular lymphomas: final results of the LL01 randomized trial of the Gruppo Italiano per lo Studio dei Linfomi. <i>Journal of Clinical Oncology</i> , 2003 , 21, 1459-65	2.2	20
8	Vinblastine, bleomycin, and methotrexate chemotherapy plus irradiation for patients with early-stage, favorable Hodgkin lymphoma: the experience of the Gruppo Italiano Studio Linfomi. <i>Cancer</i> , 2003 , 98, 2393-401	6.4	24
7	Prospective study of indolent non-follicular non-Hodgkin lymphoma: validation of Gruppo Italiano per lo studio dei linfomi (GISL) prognostic criteria for watch and wait policy. <i>Leukemia and Lymphoma</i> , 2002 , 43, 1933-8	1.9	7

6	Bleomycin, epidoxorubicin, cyclophosphamide, vincristine and prednisone (BACOP) in patients with follicular non-Hodgkin's lymphoma: results of a prospective, multicenter study of the Gruppo Italiano Per Lo Studio Dei Linfomi (GISL). <i>Leukemia and Lymphoma</i> , 2002 , 43, 1795-801	1.9	5
5	Feasibility of a mixed inpatient-outpatient model of peripheral blood stem cell transplantation for multiple myeloma. <i>Haematologica</i> , 2002 , 87, 1192-9	6.6	31
4	Peripheral blood CD38 expression predicts survival in B-cell chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2001 , 25, 927-32	2.7	45
3	Surface CD14 positivity in B-cell chronic lymphocytic leukaemia is related to clinical outcome. <i>British Journal of Haematology</i> , 1999 , 107, 347-52	4.5	11
2	In vitro drug-induced cytotoxicity predicts clinical response to fludarabine in B-cell chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 1998 , 102, 528-31	4.5	11
1	Diagnostic and Prognostic Relevance of the Immunophenotype in Acute Myelocytic Leukemia. <i>Tumori</i> , 1991 , 77, 28-31	1.7	8